Overview

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb